Whilst armchair critics think the FDA is opposed to stem-cell treatments, there are many dozens of trials underway in the US, which have been cleared by the FDA for trials - the US trials website (https://clinicaltrials.gov actually lists 8744 returns for stem-cell trials). The most recent one announcing success (as I post on here weekly lately) is in macular degeneration:
https://www.ophthalmologytimes.com/view/discovery-by-usc-investigators-shows-long-term-viability-of-stem-cell-derived-retinal-implant
The worse advertisement in the US for stem-cells was the blinding of three US women five years ago by cowboy Doctors applying MSc stem-cells (and other blood based plasmas) with no idea what they were doing.
Its not insignificant for the regulatory backdrop of OCC and other stem-cell companies that progress as been made in the very area of bad press for stem-cells in the US, in an FDA cleared trial. Roll on OCC's proposed phase III ATI trial in the US, hopefully partnered by DePuy.
- Forums
- ASX - By Stock
- FDA significance
Whilst armchair critics think the FDA is opposed to stem-cell...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.0¢ |
Change
-0.015(3.23%) |
Mkt cap ! $94.30M |
Open | High | Low | Value | Volume |
47.0¢ | 47.0¢ | 44.8¢ | $101.0K | 221.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6739 | 44.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 9799 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4539 | 0.445 |
3 | 82109 | 0.440 |
2 | 19005 | 0.430 |
1 | 40000 | 0.425 |
3 | 18904 | 0.420 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 9799 | 1 |
0.455 | 30999 | 1 |
0.465 | 7230 | 2 |
0.470 | 59673 | 2 |
0.475 | 20000 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online